Kairos Pharma, LTD.
KAPA- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001962011
No open-market purchases or sales by Kairos Pharma, LTD. insiders were filed in the last 90 days; 14 institutions reported holding it in 13F filings for Q2 2026, worth $371.1K in total; no superinvestor holds it.
13F holders, Q4 2025
Institutional positions in Kairos Pharma, LTD. as of Dec 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 14
- 0 vs. Q3 2025
- Shares held
- 855.7K
- +410.7K (+92.3%) vs. Q3 2025
- Total value
- $607.5K
- +$101.6K (+20.1%) vs. Q3 2025
- New holders
- 5
- 3 more added
- Sold out
- 5
- 2 more reduced
Compare with Q3 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting KAPA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 14 | $371.1K |
| Q1 2026 | 11 | $341.5K |
| Q4 2025 | 14 | $607.5K |
| Q3 2025 | 14 | $505.8K |
| Q2 2025 | 10 | $172.9K |
| Q1 2025 | 8 | $1.46M |
| Q4 2024 | 5 | $618.3K |
| Q3 2024 | 2 | $70.0K |
| Q2 2024 | 0 | $0 |
| Q1 2024 | 0 | $0 |
| Q4 2023 | 0 | $0 |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2025
Shares, value and share of portfolio for each institution holding Kairos Pharma, LTD.; share changes are against Q3 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Citadel Advisors LLC | 321,738 | $228.4K | 0.00% | +321,738 | New |
| Vanguard Group Inc | 131,828 | $93.6K | 0.00% | 00.0% | Unchanged |
| Two Sigma Investments, LP | 94,008 | $66.7K | 0.00% | +48,219+105.3% | Added |
| Geode Capital Management, LLC | 72,833 | $51.7K | 0.00% | +7,033+10.7% | Added |
| XTX Topco Ltd | 48,494 | $34.4K | 0.00% | +36,086+290.8% | Added |
| SevenBridge Financial Group, LLC | 44,286 | $31.9K | 0.01% | 00.0% | Unchanged |
| Aptus Capital Advisors, LLC | 44,286 | $31.4K | 0.00% | 00.0% | Unchanged |
| State Street Corp | 24,100 | $17.1K | 0.00% | 00.0% | Unchanged |
| HRT Financial LP | 21,319 | $15.0K | 0.00% | +21,319 | New |
| Virtu Financial LLC | 20,278 | $14.0K | 0.00% | +20,278 | New |
| Two Sigma Advisers, LP | 15,142 | $10.8K | 0.00% | +15,142 | New |
| Advisor Group Holdings, Inc. | 13,045 | $9.26K | 0.00% | +13,045 | New |
| Tower Research Capital LLC (TRC) | 4,227 | $3.00K | 0.00% | −1,730−29.0% | Reduced |
| Bank of America Corp | 134 | $95 | 0.00% | −170−55.9% | Reduced |
| Two Sigma Securities, LLC | 0 | $0 | 0.00% | −24,895−100.0% | Sold out |
| FNY Investment Advisers, LLC | 0 | $0 | 0.00% | −23,500−100.0% | Sold out |
| Quadrature Capital Ltd | 0 | $0 | 0.00% | −14,887−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −5,979−100.0% | Sold out |
| Royal Bank of Canada | 0 | $0 | 0.00% | −1,000−100.0% | Sold out |